Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins
The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
1. A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a polypeptide comprising:
(A)(a) an N-terminal domain comprising a first fibronectin type III tenth domain ( 10 Fn3), wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); and (iii) binds to insulin-like growth factor-I receptor (IGF-IR) with a K D of less than 500 nM; and
(b) a C-terminal domain comprising a second fibronectin type III tenth domain ( 10 Fn3), wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); and (iii) binds to vascular endothelial growth factor receptor 2 (VEGFR2) with a K D of less than 500 nM;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence of any one of SEQ ID NOs: 8-11, 29-31, and 63-70;
(B)(a) an N-terminal domain comprising a first 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to VEGFR2 with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 40; and
(b) a C-terminal domain comprising a second 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to IGF-IR with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 35;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20;
(C)(a) an N-terminal domain comprising a first 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to IGF-IR with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 35; and
(b) a C-terminal domain comprising a second 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to VEGFR2 with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 40;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20;
(D)(a) an N-terminal domain comprising a first 10 Fn3 domain which binds to IGF-IR, wherein the 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 2, 3, and 4, respectively; and
(b) a C-terminal domain comprising a second 10 Fn3 domain which binds to VEGFR2, wherein the second 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 5, 6, and 7, respectively; or
(E)(a) an N-terminal domain comprising a first 10 Fn3 domain which binds to VEGFR2, wherein the 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 5, 6, and 7, respectively; and
(b) a C-terminal domain comprising a second 10 Fn3 domain which binds to IGF-IR, wherein the second 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 2, 3, and 4, respectively.
2. The method of claim 1 , wherein the first and/or second 10 Fn3 domain comprises an N-terminal extension sequence selected from the group consisting of M, MG, G, SEQ ID NO: 45, SEQ ID NO: 46, and SEQ ID NO: 48.
3. The method of claim 1 , wherein the first and/or second 10 Fn3 domain is linked at its C-terminus to the amino acid sequence of E, EI, ES, EC, EGS, EGC, EID, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 71, or SEQ ID NO: 72.
4. The method of claim 1 , wherein the polypeptide further comprises one or more pharmacokinetic (PK) moieties selected from the group consisting of: a polyoxyalkylene moiety, a human serum albumin binding protein, sialic acid, human serum albumin, IgG, an IgG binding protein, transferrin, and an Fc fragment.
5. The method of claim 4 , wherein the PK moiety and the polypeptide are linked via at least one disulfide bond, a peptide bond, a polypeptide, a polymeric sugar, or a polyethylene glycol moiety.
6. The method of claim 1 , wherein the polypeptide has been deimmunized to remove one or more T-cell epitopes.
7. The method of claim 1 , wherein the IGF-IR binding 10 Fn3 domain binds to IGF-IR with a KD of less than 500 nM.
8. The method of claim 1 , wherein the VEGFR2 binding 10 Fn3 domain binds to VEGFR2 with a KD of less than 500 nM.
9. The method of claim 1 , wherein the polypeptide comprises:
(a) an N-terminal domain comprising a first 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); and (iii) binds to IGF-IR with a K D of less than 500 nM; and
(b) a C-terminal domain comprising a second 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); and (iii) binds to VEGFR2 with a K D of less than 500 nM;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20, wherein the polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence of any one of SEQ ID NOs: 8-11, 29-31, and 63-70.
10. The method of claim 1 , wherein the polypeptide comprises:
(a) an N-terminal domain comprising a first 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has atleast one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to VEGFR2 with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 40; and
(b) a C-terminal domain comprising a second 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to IGF-IR with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 35;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20.
11. The method of claim 1 , wherein the polypeptide comprises:
(a) an N-terminal domain comprising a first 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to IGF-IR with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 35; and
(b) a C-terminal domain comprising a second 10 Fn3 domain, wherein the 10 Fn3 domain (i) comprises a loop, AB; a loop, BC; a loop, CD; a loop, DE; a loop, EF; and a loop, FG; (ii) has at least one loop selected from loop BC, DE, and FG with an altered amino acid sequence relative to the sequence of the corresponding loop of the human 10 Fn3 domain (SEQ ID NO: 1); (iii) binds to VEGFR2 with a K D of less than 500 nM; and (iv) is at least 85% identical to SEQ ID NO: 40;
wherein the first and second 10 Fn3 domains are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker or the amino acid sequence of SEQ ID NO: 20.
12. The method of claim 1 , wherein the polypeptide comprises:
(a) an N-terminal domain comprising a first 10 Fn3 domain which binds to IGF-IR, wherein the 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 2, 3, and 4, respectively; and
(b) a C-terminal domain comprising a second 10 Fn3 domain which binds to VEGFR2, wherein the second 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 5, 6, and 7, respectively.
13. The method of claim 12 , wherein the first 10 Fn3 domain and second 10 Fn3 domain are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 20.
14. The method of claim 1 , wherein the polypeptide comprises:
(a) an N-terminal domain comprising a first 10 Fn3 domain which binds to VEGFR2, wherein the 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 5, 6, and 7, respectively; and
(b) a C-terminal domain comprising a second 10 Fn3 domain which binds to IGF-IR, wherein the second 10 Fn3 domain comprises BC, DE, and FG loops comprising the amino acid sequence set forth in SEQ ID NOs: 2, 3, and 4, respectively.
15. The method of claim 14 , wherein the first 10 Fn3 domain and second 10 Fn3 domain are linked via a polypeptide selected from a glycine-serine based linker, a glycine-proline based linker, a proline-alanine based linker, or a polypeptide comprising the amino acid sequence of SEQ ID NO: 20.